With President-Elect Trump headed for the Oval Office and the GOP controlling both houses of Congress, the small-business trade group believes Republican Congressman Pete Sessions’ Safe Cosmetics Modernization Act could get a more earnest look this year. Reintroduced today, the bill proposes comprehensive federal preemption to ensure national uniformity in cosmetic regulations.
The Independent Cosmetic Manufacturers and Distributors is inviting larger firms beyond its membership to get behind federal cosmetics legislation that was overshadowed in the last session by the Personal Care Products Safety Act, with renewed optimism for the industry-friendly bill in the new political environment.
The Cosmetic Modernization Amendments of 2015, sponsored by Rep. Pete Sessions, R-Texas, received little attention in the 114th Congress, when...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
